Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-γ and TNF-α on apoptosis

Journal of Neuroscience Research

Volumn 76, Issue 6, 2004, Pages 834-845

  Buntinx, Mieke ^a   Moreels, Marjan ^a   Vandenabeele, Frank ^a   Lambrichts, Ivo ^a   Raus, Jef ^a   Steels, Paul ^a   Stinissen, Piet ^a   Ameloot, Marcel ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

HOG; MO3.13; Multiple sclerosis; Oligodendrocyte

Indexed keywords

CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CYTOTOXICITY; DEMYELINATING DISEASE; HUMAN; HUMAN CELL; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL CULTURE; NEUROLOGIC DISEASE; OLIGODENDROGLIA; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY;

ANNEXIN A5; APOPTOSIS; CELLS, CULTURED; DRUG SYNERGISM; HUMANS; INTERFERON TYPE II; OLIGODENDROGLIA; PHOSPHATIDYLSERINES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642513275     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20118     Document Type: Article

References (55)

1. Agresti C, D'Urso D, Levi G. 1996. Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur J Neurosci 8:1106-1116.
2. Akassoglou K, Bauer J, Kassiotis G, Pasparakis M, Lassmann H, Kollias G, Probert L. 1998. Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy. Am J Pathol 153:801-813.
3. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. 1997. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 158:438-445.
4. Andrews T, Zhang P, Bhat NR. 1998. TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res 54:574-583.
5. Baerwald KD, Popko B. 1998. Developing and mature oligodendrocytes respond differently to the immune cytokine interferon-gamma. J Neurosci Res 52:230-239.
6. Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W. 2000. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29:366-375.
7. Bonetti B, Raine CS. 1997. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 42:74-84.
8. Brosnan CF, Raine CS. 1996. Mechanisms of immune injury in multiple sclerosis. Brain Pathol 6:243-257.
9. Buntinx M, Stinissen P, Steels P, Ameloot M, Raus J. 2002. Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions. Crit Rev Immunol 22:391-424.
10. Buntinx M, Vanderlocht J, Hellings N, Vandenabeele F, Lambrichts I, Raus J, Ameloot M, Stinissen P, Steels P. 2003. Characterization of three human oligodendroglial cell lines as a model to study oligodendrocyte injury in multiple sclerosis: morphology and oligodendrocyte-specific gene expression. J Neurocytol 32:25-38.
11. Cannella B, Raine CS. 1995. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37:424-435.
12. Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B. 1996. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol Cell Neurosci 7:354-370.
13. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS. 1997. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 3:73-76.
14. D'Souza S, Alinauskas K, McCrea E, Goodyer C, Antel JP. 1995. Differential susceptibility of human CNS-derived cell populations to TNF-dependent and independent immune-mediated injury. J Neurosci 15: 7293-7300.
15. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS, Antel JP. 1996. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 184:2361-2370.
16. Debruyne J, Philippe J, Dereuck J, Willems A, Leroux-Roels G. 1998. Relapse markers in multiple sclerosis: are in vitro cytokine production changes reflected by circulatory T-cell phenotype alterations? Mult Scler 4:193-197.
17. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M. 1997. Cell death and birth in multiple sclerosis brain. J Neurol Sci 149: 1-11.
18. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J, Hauser SL. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 92:3601-3605.
19. Hermans G, Stinissen P, Hauben L, Berg-Loonen E, Raus J, Zhang J. 1997. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 42:18-27.
20. Hisahara S, Shoji S, Okano H, Miura M. 1997. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 69:10-20.
21. Horwitz MS, Evans CF, McGavern DB, Rodriguez M, Oldstone MB. 1997. Primary demyelination in transgenic mice expressing interferon-gamma. Nat Med 3:1037-1041.
22. Kassiotis G, Kollias G. 2001. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 193:427-434.
23. Kong GY, Kristensson K, Bentivoglio M, 2002. Reaction of mouse brain oligodendrocytes and their precursors, astrocytes and microglia, to proinflammatory mediators circulating in the cerebrospinal fluid. Glia 37:191-205.
24. Ladiwala U, Li H, Antel JP, Nalbantoglu J. 1999. p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. J Neurochem 73:605-611.
25. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW. 1993. Cytokine production by human fetal microglia and a strocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 150:2659-2667.
26. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274.
27. Martino G, Consiglio A, Franciotta DM, Corti A, Filippi M, Vandenbroeck K, Sciacca FL, Comi G, Grimaldi LM. 1997. Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis. J Neurol Sci 152:51-61.
28. McLaurin J, D'Souza S, Stewart J, Blain M, Beaudet A, Nalbantoglu J, Antel JP. 1995a. Effect of tumor necrosis factor alpha and beta on human oligodentrocytes and neurons in culture. Int J Dev Neurosci 13:369-381,
29. McLaurin J, Trudel GC, Shaw IT, Antel JP, Cashman NR. 1995b. A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol 26:283-293.
30. Melcangi RC, Cavarretta I, Magnaghi V, Ciusani E, Salmaggi A. 2000. Corticosteroids protect oligodendrocytes from cytokine-induced cell death. Neuroreport 11:3969-3972.
31. Molina-Holgado E, Vela JM, Arevalo-Martin A, Guaza C. 2001. LPS/ IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur J Neurosci 13:493-502.
32. Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, Lassmann H. 1994. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 117:1311-1322.
33. Panitch HS, Hirsch RL, Schindler J, Johnson KP. 1987. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37:1097-1102.
34. Pender MP, Nguyen KB, McCombe PA, Kerr JF. 1991. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 104:81-87.
35. Popko B, Corbin JG, Baerwald KD, Dupree J, Garcia AM. 1997. The effects of interferon-gamma on the central nervous system. Mol Neurobiol 14:19-35.
36. Post GR, Dawson G. 1992. Characterization of a cell line derived from a human oligodendroglioma. Mol Chem Neuropathol 16:303-317.
37. Pouly S, Becher B, Blain M, Antel JP. 2000. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J Neuropathol Exp Neurol 59:280-286.
38. Prineas JW, McDonald WI. 1997. Demyelinating diseases. In: Graham DI, Lantos PL, editors. Greenfield's neuropathology. London: Arnold. p 813-895.
39. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. 1995. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Natl Acad Sci USA 92:11294-11298.
40. Raine CS. 1995. Multiple sclerosis: TNF revisited, with promise. Nat Med 1:211-214.
41. Raine CS. 1997. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 77:135-152.
42. Scurlock B, Dawson G. 1999. Differential responses of oligodendrocytes to tumor necrosis factor and other pro-apoptotic agents: role of ceramide in apoptosis. J Neurosci Res 55:514-522.
43. Selmaj KW, Raine CS. 1988. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339-346.
44. Selmaj K, Raine CS, Cannella B, Brosnan CF. 1991a, Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87:949-954.
45. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. 1991b. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 147:1522-1529.
46. Selmaj K, Walczak A, Mycko M, Berkowicz T, Kohno T, Raine CS. 1998. Suppression of experimental autoimmune encephalomyelitis with a TNF binding protein (TNFbp) correlates with down-regulation of VCAM-1/ VLA-4. Eur J Immunol 28:2035-2044.
47. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. 1997. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol 27:905-913.
48. Thomson A. 1994. The cytokine handbook (2nd ed). London: Academic Press.
49. Torres C, Aranguez I, Rubio N. 1995. Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens. Immunology 86:250-255.
50. Traugott U, Lebon P. 1988. Demonstration of alpha, beta, and gamma interferon in active chronic multiple sclerosis lesions. Ann N Y Acad Sci 540:309-311.
51. van Engeland M, Nieland LJ, Ramaekers FC, Schuite B, Reutelingsperger CP. 1998. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9:
52. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47:1531-1534.
53. Vandevyver C, Motmans K, Stinissen P, Zhang J, Raus J. 1998. Cytokine mRNA profile of myelin basic protein reactive T-cell clones in patients with multiple sclerosis. Autoimmunity 28:77-89.
54. Vartanian T, Li Y, Zhao M, Stefansson K. 1995. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med 1:732-743.
55. Ye P, D'Ercole AJ. 1999. Insulin-like growth factor I protects oligodendrocytes from tumor necrosis factor-alpha-induced injury. Endocrinology 140:3063-3072.